Prevalence of production of virus-specific interferon-γ among seronegative hepatitis C-resistant subjects reporting injection drug use

Anthony J. Freeman, Rosemary A. Ffrench, Jeffrey J. Post, Charles E. Harvey, Stuart J. Gilmour, Peter A. White, George Marinos, Ingrid Van Beek, William D. Rawlinson, Andrew R. Lloyd

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

This report describes subjects who were highly likely to have been repeatedly exposed to hepatitis C virus (HCV) through injection drug use and who remained negative for anti-HCV antibody. Production of virus-specific interferon-γ by peripheral blood mononuclear cells was seen in the majority of subjects (72%) and was associated with higher-risk behavior. For 92% of the subjects, results of recombinant immunoblot assays demonstrated faint bands against nonstructural proteins. The immune responses described are likely to have been primed and maintained by episodes of subclinical infection without classic seroconversion and may indicate a hepatitis C-resistant phenotype. Vaccine strategies to mimic this response may provide protection against persistent HCV infection.

Original languageEnglish
Pages (from-to)1093-1097
Number of pages5
JournalJournal of Infectious Diseases
Volume190
Issue number6
DOIs
Publication statusPublished - 15 Sep 2004
Externally publishedYes

Cite this

Freeman, A. J., Ffrench, R. A., Post, J. J., Harvey, C. E., Gilmour, S. J., White, P. A., Marinos, G., Van Beek, I., Rawlinson, W. D., & Lloyd, A. R. (2004). Prevalence of production of virus-specific interferon-γ among seronegative hepatitis C-resistant subjects reporting injection drug use. Journal of Infectious Diseases, 190(6), 1093-1097. https://doi.org/10.1086/422605